A host of corporate and government-backed initiatives have been launched to tackle the coronavirus that develops into the Covid-19 disease. In a global, fast-moving pandemic, this can only be a snapshot of the efforts at the end of March 2020.

The SiBionics-backed heart disease device developer secured $28.4m in a round led by SDIC Gaoxin Industrial Investment.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Partners Healthcare and Medison Pharma-backed Keros Therapeutics floated at the top of its range and will look to advance its musculoskeletal disorder drug candidates.

The remote diagnostics technology developer increased its total funding to $105m in a round co-led by new investor Qualcomm Ventures.

Mutual insurer Sham has led a $20m round for healthcare cybersecurity software provider CyberMDX that expanded its total funding to $30m.

The translational medicine-focused research services provider, which counts Renfu Pharmaceutical as an investor, has completed a Humanwell-backed round sized at about $56m.

Chishima Real Estate and Miraca helped add $6.8m to extend Kringle‘s latest round to $15.5m which will fund development of its rare disease treatments.

Lepu Medical and Shandong Buchang Pharma were among the limited partners that have backed the healthcare investor's latest fund.

Novo and Takeda are set to exit antibody therapy developer Symphogen in an acquisition by one of its strategic partners, Servier.